Filing Flows

Filing Flows › Companies › Altimmune › Cash flow

Altimmune cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$24.3M in Q2 2026 · −$76.6M over twelve months

Operating cash flow−$24.2M
Capital spending−$32K
Free cash flow−$24.3M

Analysis

In Q2 2026, Altimmune generated −$24.2M of operating cash flow and spent $32K on capital projects, leaving free cash flow of −$24.3M. That is $4.9M less than in Q2 2025 (−$19.4M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$76.5M; the largest uses were other investing ($454M), operating cash flow ($76.5M), capital spending ($54K); besides operations, cash came from other financing ($300M), shares issued ($110M); the cash balance fell by $120M.

Operating cash flow was −$24.2M against net income of −$22.8M. The largest differences: prepaid and other assets −$3.7M, stock-based pay +$2.8M, receivables −$1.7M.

Free cash flow

Altimmune: free cash flow by quarterAltimmune: free cash flow by quarter−$27.1MQ3 2024−$18.3MQ4 2024−$16.8MQ1 2025−$19.4MQ2 2025−$11.9MQ3 2025−$19.4MQ4 2025−$21.0MQ1 2026−$24.3MQ2 2026
Operating cash flow less capital spending.
Altimmune: operating cash flow against capital spendingAltimmune: operating cash flow against capital spendingOperating cash flowCapital spending−$27.1M$0Q3 2024−$18.3M$0Q4 2024−$16.8M$0Q1 2025−$19.4M$0Q2 2025−$11.9M$0Q3 2025−$19.4M$1KQ4 2025−$20.9M$21KQ1 2026−$24.2M$32KQ2 2026
Latest (Q2 2026): Operating cash flow −$24.2M, Capital spending $32K.

Capital allocation, year by year

Altimmune: where the cash came from (up) and went (down), by fiscal yearAltimmune: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$78.2MFY2021: Shares issued $65.0MFY2021: Capital spending −$12.1M$65.0MFY2021FY2022: Operating cash flow −$62.6MFY2022: Shares issued $57.1MFY2022: Capital spending −$126K$57.1MFY2022FY2023: Operating cash flow −$75.8MFY2023: Shares issued $86.7MFY2023: Capital spending −$47K$86.7MFY2023FY2024: Operating cash flow −$79.8MFY2024: Shares issued $10.4M$10.4MFY2024FY2025: Operating cash flow −$67.5MFY2025: Net borrowing $35.0MFY2025: Shares issued $174MFY2025: Capital spending −$11K$209MFY2025
Over these 5 years operating cash flow totalled −$364M; the largest uses were operating cash flow ($364M) and capital spending ($12.3M). Cash-flow statements as filed.

Where the cash came from and went

Altimmune: sources (+) and uses (−) of cash, Q2 2026Altimmune: sources (+) and uses (−) of cash, Q2 2026Other investing−$221MOther financing$211MCash drawn (+) / kept (−)$34.6MOperating cash flow−$24.2MShares issued−$89KCapital spending−$32K
Altimmune: sources (+) and uses (−) of cash, TTM to Q2 2026Altimmune: sources (+) and uses (−) of cash, TTM to Q2 2026Other investing−$454MOther financing$300MCash drawn (+) / kept (−)$120MShares issued$110MOperating cash flow−$76.5MCapital spending−$54K

From profit to cash

Altimmune: net income to operating cash flow, Q2 2026Altimmune: net income to operating cash flow, Q2 2026Net income−$22.8MDepreciation & amortization$23KStock-based pay$2.8MReceivables−$1.7MPayables−$258KAccrued liabilities$1.4MPrepaid and other assets−$3.7MOperating cash flow−$24.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$24.2M−$32K—−$89K$34.6M−$24.3M
Q1 2026−$20.9M−$21K—$8.9M−$53.8M−$21.0M
Q4 2025−$19.4M−$1K$20.0M$61.6M$17.5M−$19.4M
Q3 2025−$11.9M——$39.8M$122M−$11.9M
Q2 2025−$19.4M——$37.5M−$134M−$19.4M
Q1 2025−$16.8M——$34.8M−$12.2M−$16.8M
Q4 2024−$18.3M——$93K−$5.5M−$18.3M
Q3 2024−$27.1M——$139K$25.7M−$27.1M

Altimmune: income statement and cash flow

Altimmune, Q4 2025: revenue $26K (+420% year over year). The chart follows the revenue to costs, profit and cash.

Altimmune: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.